Sanofi SA banner

Sanofi SA
MIL:1SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
MIL:1SAN
Watchlist
Price: 76.95 EUR -0.71% Market Closed
Market Cap: €96.3B

Relative Value

The Relative Value of one 1SAN stock under the Base Case scenario is hidden EUR. Compared to the current market price of 76.95 EUR, Sanofi SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

1SAN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

1SAN Competitors Multiples
Sanofi SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Sanofi SA
MIL:1SAN
94.2B EUR 2 12.1 10.1 10.1
US
Eli Lilly and Co
NYSE:LLY
860.3B USD 13.1 41.3 27.9 29.8
US
Johnson & Johnson
NYSE:JNJ
566.9B USD 6 21.1 14.7 18.1
CH
Roche Holding AG
SIX:ROG
243.3B CHF 3.9 18.8 11.2 12.6
UK
AstraZeneca PLC
LSE:AZN
213.1B GBP 4.9 28 15.6 22
US
Merck & Co Inc
NYSE:MRK
286.3B USD 4.4 15.8 9.8 11.9
CH
Novartis AG
SIX:NOVN
222.8B CHF 5.1 20.7 12.8 16.5
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.3 7.6 8.9
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
115.5B USD 2.4 16.4 7 8.6
P/E Multiple
Earnings Growth PEG
FR
Sanofi SA
MIL:1SAN
Average P/E: 20.4
12.1
16%
0.8
US
Eli Lilly and Co
NYSE:LLY
41.3
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.1
7%
3
CH
Roche Holding AG
SIX:ROG
18.8
14%
1.3
UK
AstraZeneca PLC
LSE:AZN
28
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Sanofi SA
MIL:1SAN
Average EV/EBITDA: 45.4
10.1
19%
0.5
US
Eli Lilly and Co
NYSE:LLY
27.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.6
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
CH
Novartis AG
SIX:NOVN
12.8
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Sanofi SA
MIL:1SAN
Average EV/EBIT: 99.1
10.1
12%
0.8
US
Eli Lilly and Co
NYSE:LLY
29.8
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.1
6%
3
CH
Roche Holding AG
SIX:ROG
12.6
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
22
21%
1
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
CH
Novartis AG
SIX:NOVN
16.5
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.6
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett